BioLife Solutions (BLFS) Projected to Post Quarterly Earnings on Monday

BioLife Solutions (NASDAQ:BLFS) will likely be issuing its quarterly earnings data before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $21.73 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $26.67 on Monday. The firm’s fifty day moving average price is $26.93 and its two-hundred day moving average price is $25.51. The stock has a market cap of $1.24 billion, a PE ratio of -25.16 and a beta of 1.91. BioLife Solutions has a fifty-two week low of $14.50 and a fifty-two week high of $29.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

Wall Street Analyst Weigh In

BLFS has been the topic of a number of research reports. KeyCorp boosted their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Craig Hallum boosted their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Northland Securities boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Benchmark reissued a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, TD Cowen boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.43.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the sale, the chief financial officer now owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Aby J. Mathew sold 7,604 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the sale, the executive vice president now directly owns 276,315 shares in the company, valued at $7,551,688.95. This trade represents a 2.68 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,678 shares of company stock valued at $317,990. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.